This review helps pharmacists position finerenone across the CKD spectrum, distinguish it from steroidal mineralocorticoid receptor antagonists, and manage its hyperkalemia and eGFR-dip profile.
Bottom Line
Finerenone now has randomized evidence for cardiorenal protection across type 2 diabetic and non-diabetic albuminuric chronic kidney disease (CKD), and should be considered as an add-on to maximally tolerated renin-angiotensin system (RAS) blockade with a structured potassium monitoring plan rather than reserved for advanced disease.
HR 0.82
kidney composite, FIDELIO-DKD
0.7 ml/min/1.73 m2/yr
slower eGFR decline, FIND-CKD
HR 0.71
HF hospitalization, FIGARO-DKD
~20%
at-risk patients getting UACR testing
State of Play
Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), is established for cardiorenal protection in type 2 diabetes (T2D) with albuminuric CKD on the basis of the FIDELIO-DKD and FIGARO-DKD trials, and is endorsed by Kidney Disease: Improving Global Outcomes (KDIGO) and American Diabetes Association (ADA) guidance. Its mechanism, pharmacokinetics, and outcome data increasingly separate it from steroidal MRAs such as spironolactone. New trial data are now pushing its documented role into non-diabetic CKD.
🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Want the full review?
Subscribe to PharmD Signal for the complete evidence synthesis and practice recommendations on every topic, plus every deep analysis we publish.
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.